Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$13.69M, compared with $15.19M a year earlier. Trailing-twelve-month net income was -$44.17M. Over 3 fiscal years it compounded at -28.2% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$56.23M (+267.9%) for the fiscal year ending Dec 2026, a step up from the -75.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.69M+11.1% QoQ
- Last fiscal yearDec 2025
- -$15.28M-75.5% YoY
- LTMMar 2026
- -$44.17M+6.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -190.1% | +79.1% | +269.3 pp |
| 1 year | -75.5% | +267.9% | +343.4 pp |
| 3-year CAGR | -28.2% | +67.4% | +95.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (15.28M) USD
- Year-over-year change
- +75.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.28M) | +75.5% |
| FY2024 | 2024-12-31 | (62.29M) | -130.5% |
| FY2023 | 2023-12-31 | (27.03M) | +34.6% |
| FY2022 | 2022-12-31 | (41.31M) | +4.5% |
| FY2021 | 2021-12-31 | (43.24M) | — |
Net Income vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.7% is the 6th highest of 8, against a peer median of +26.1%.
- Over three fiscal years its annual growth of -28.2% compares with a peer median of -14.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $465.5M USD | +369.3% | — | 992.9% | |
| LTM Jun 2026 | $460M USD | +54.4% | +9.8% | 393.2% | |
| LTM Jun 2026 | $157.13M USD | +28.5% | -23.6% | 287.8% | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $68.17M USD | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $59.14M USD | -242.2% | -44.1% | 166.4% | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Mar 2026 | $44.17M USD | +6.7% | -28.2% | — | |
| LTM Dec 2025 | $35.34M USD | — | — | 48.6% | |
| LTM Jun 2024 | $31.85M USD | — | -39.6% | 3904.3% | |
| Peer median (excluding CRVS) | — | +26.1% | -14.6% | 340.5% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.23M | 2.69M | 2.15M | 3M | 5.33M |
| Change in Working Capital | (3.24M) | 1.41M | (3.59M) | (1.65M) | 3.58M |
| Accounts Receivables | (507K) | (81K) | 562K | (49K) | 38K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.9M) | 411K | (451K) | 1.06M | (91K) |
| Other Working Capital | (827K) | 1.08M | (3.71M) | (2.66M) | 3.63M |
| Other Non-Cash Items | 5.07M | 9.81M | 4.39M | 35.43M | (26.53M) |
| Operating Cash Flow | (36.72M) | (27.02M) | (23.94M) | (25.42M) | (32.8M) |
| Capital Expenditures | (5K) | (269K) | (34K) | 0 | (174K) |
| Acquisitions (Net) | (21.57K) | 22K | 0 | 5K | 0 |
| Purchases of Investments | (9.36M) | (66.19M) | (47.05M) | (70.12M) | (91.75M) |
| Sales of Investments | 30.92M | 43.16M | 62.62M | 42.63M | 84.13M |
| Other Investing Activities | 21.57K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 21.56M | (23.28M) | 15.54M | (27.48M) | (7.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 60.94M | 0 | 7.84M | 16.41M | 36.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 12K | 32.62M | 0 |
| Financing Cash Flow | 62.16M | 0 | 7.86M | 49.03M | 36.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47M | (50.3M) | (539K) | (3.88M) | (4.16M) |
| Free Cash Flow | (36.72M) | (27.29M) | (23.97M) | (25.42M) | (32.97M) |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.